Present situation and perspectives of antimycotics with systemic effect;Současný stav a perspektivy antimykotik se systémovým účinkem

Casopis Lekaru Ceskych

Volumn 140, Issue 19, 2001, Pages 596-604

  Haber, J ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Amphotericin B; Azoles; Echinocandins; Efflux pump inhibitors; Fluconazole; Itraconazole; Ketoconazole; Nystatine; Posaconazole; Pradimicines; Ravuconazole; Sordarines; Variconazole

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; ASTEMIZOLE; BENANOMICIN A; BMS 181184; CANDIDAS; CASPOFUNGIN; CISAPRIDE; DACTARIN; ECHINOCANDIN B DERIVATIVE; FLUCONAZOLE; FLUCYTOSINE; GW 471558; GW 531920; ITRACONAZOLE; KETOCONAZOLE; LY 30366; MC 510027; MEVINOLIN; MICAFUNGIN; MICONAZOLE; MIDAZOLAM; MILBEMYCIN; NIKKOMYCIN Z; NP 3278; NYSTATIN; POSACONAZOLE; POSAKONAZOLE; PRADIMICIN A; PRADIMICIN B; PRADIMICIN C; RAVUCONAZOLE; SAMPANGINE; SORDARIN DERIVATIVE; TERBINAFINE; UK 109; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORICONAZOLE;

AREA UNDER THE CURVE; DISTRIBUTION VOLUME; DRUG CLEARANCE; DRUG COST; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NEPHROTOXICITY; REVIEW; SYSTEMIC MYCOSIS; CHEMISTRY; MYCOSIS;

ANTIFUNGAL AGENTS; HUMANS; MYCOSES;

EID: 0034797998     PISSN: 00087335     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (69)

1. Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice
2. Safety, plasma concentrations, and efficacy of high-dose fluconazole in invasive mold infections
3. Infusion-related toxicity of three different amphotericin B formulations and its relation to cytokine plasma levels
4. Resistance to antimicrobial agents, Monte Carlo 8.-11.10.1997 (zpráva o kongresu)
5. Antifungal agents
6. AmBisome (liposomal amphotericin B). A comparative review
7. Amphotericin B. Current understanding of mechanisms of action
8. Prevention of Amphotericin B-Induced Renal Impairment. A Review of the Use of Sodium Supplementation
9. Translation elongation factor 2 is part of the target for a new family of antifungals
10. In vitro antifungal activity of liposomal nystatin in comparison with nystatin, amphotericin B cholesteryl sulphate, liposomal amphotericin B, amphotericin B lipid complex, amphotericin B desoxycholate, fluconazole and itraconazole
11. A comparative analysis of lipid-complexed and liposomal amphotericin B preparations in haematological oncology
12. Cytokine expression amphotericin B (AmB) formulation
13. Tissue concentrations and bioactivity of amphotericin B in cancer patients treated with amphotericin B - Deoxycholate
14. Liposomal amphotericin B therapeutic use in the management of fungal infections and visceral leishmaniasis
15. Susceptibility of fluconazole-resistant clinical isolates of Candida spp. to echinocandin LY303366, itraconazole and amphotericin B
16. Itraconazole pharmacology, clinical experience and future development
17. Clinical pharmacokinetics of fluconazole
18. Aspergillosis diagnosis and treatment
19. Echinocandins and pneumocandins - A new antifungal class with a novel mode of action
20. Dose range evaluation of liposomal nystatin and comparisons with amphotericin B and amphotericin B lipid complex in temporality neutropenic mice infected with an isolate of Aspergillus fumigatus with reduced susceptibility to amphotericin B
21. Sordarins. A new class of antifungals with selective inhibition of the protein synthesis elongation cycle in yeasts. Antimicrob
22. The discovery and development of amphotericin B
23. Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans
24. Empiric amphotericin B therapy the need for a reappraisal
25. In vitro antifungal and fungicidal spectra of a new pradimicin derivative, BMS-181184
26. Amphotericin B 30 years of clinical experience
27. Induction of prostaglandin synthesis as the mechanism responsible for the chills and fever produced by infusing amphotericin B
28. Fluconazole. An update of its pharmacodynamic and pharmacokinetic properties and therapeutic use in major superficial and systemic mycoses in immunocompromised patients
29. Safety and efficacy of multilamellar liposomal nystatin against disseminated candidiasis in persistently neutropenic rabbits
30. Liposomal nystatin against experimental pulmonary aspergillosis in persistently neutropenic rabbits efficacy, safety and non-compartmental pharmacokinetics
31. Fluconazol - Souhrn informací
32. Itraconazole. A reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections
33. Sordarins in vitro activities of new antifungal derivatives against pathogenic yeasts, Pneumocystis carinii, and filamentous fungi
34. Lipid formulations of amphotericin B recent progress and future directions
35. Attenuation of nephrotoxicity by a novel lipid nanosphere (NS-718) incorporating amphotericin B
36. In vitro tumor necrosis factor induction assay for analysis of febrile toxicity associated with amphotericin B preparations
37. Distribution and activity of amphotericin B in humans
38. Antifungal agents in the 1990s. Current status and future developments
39. The new antifungal azoles fluconazole and itraconazole
40. In vitro antifungal activity of nikkomycin Z in combination with fluconazole or itraconazole
41. Systemically administered antifungal agents. A review of their clinical pharmacology and therapeutic applications
42. In vitro susceptibility of 245 yeast isolates to amphotericin b, 5-fluorocytosine, ketoconazole, fluconazole and itraconazole
43. Must we really fear toxicity of conventional amphotericin B?
44. Treatment of fungal infections in patients with HIV-infection or AIDS
45. Fluconazole-resistant Candida species from HIV infected patients with recurrent Candida stomatitis cross resistance to itraconazole and ketoconazole
46. In vitro antifungal activity of FK463, a new water-soluble echinocandin-like lipopeptide
47. More inhibitors of fungal efflux pumps
48. EORTC-IFCC phase II study on liposomal nystatin in patients with invasive Aspergillus (IA) infections, refractory or intolerant to Conventional/Lipid Ampho B (AB)
49. In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi
50. International surveillance of blood stream infections due to Candida species in the European SENTRY Program species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents
51. International surveillance of blood stream infections due to Candida species frequency of occurrence and in vitro susceptibility to fluconazole, ravuconazole, and voriconazole among isolates collected from 1997 through 1999 in the United States (US), Canada (CAN), Latin America (LA, and Europe (EU) for the SENTRY Program
52. Plasma and tissue concentrations of fluconazole and their correlation to breakpoints
53. Optimisation of itraconazole therapy using target drug concentrations
54. Adhesion of Candida albicans to epithelial cells-effect of nikkomycin
55. Refractory pulmonary aspergillosis compassionate trial with terbinafine
56. L-671, 329 a new antifungal agent
57. Drug interaction studies of a glucan synthase inhibitor (LY 303366) and a chitin synthase inhibitor (Nikkomycin Z) for inhibition and killing of fungal pathogens
58. Concentrations in plasma and safety of 7 days of intravenous intraconazole followed by 2 weeks or oral itraconazole solution in patients in intensive care units
59. Fluconazole versus amphotericin B as empirical antifungal therapy of unexplained fever in granulocytpenic cancer patients a pragmatic, multicentre, prospective and randomised clinical trial
60. Empiric therapy with amphotericin B in febrile granulocytopenic patients
61. Pradimicins a novel class of broad-spectrum antifungal compounds
62. In vitro activity of BMS-181184 compared with those of cluconazole and amphotericin B against various Candida spp
63. An introduction
64. Amphotericin B colloidal dispersion vs. amphotericin B as therapy for the invasive aspergillosis
65. A pharmacokinetic study of intravenous itraconazole followed by oral administration of itraconazole capsules in patients with advanced human immunodeficiency virus infection
66. Polyene antibiotics relative degrees of in vitro cytotoxicity and potential effects on tubule phospholipid and ceramide content